|
|
Endo International Plc (ENDPQ) |
|
Price: $0.0006
$0.00 
0.000%
|
| Day's High:
| $0.0006
| Week Perf:
| 0.00
|
| Day's Low: |
$ 0.00 |
30 Day Perf: |
20 % |
| Volume (M): |
10 |
52 Wk High: |
$ 0.01 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
| Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
235 |
| Employees |
2,931 |
| Revenues (TTM) (Millions $) |
2,012 |
| Net Income (TTM) (Millions $) |
-2,450 |
| Cash Flow (TTM) (Millions $) |
-219 |
| Capital Exp. (TTM) (Millions $) |
94 |
Endo International Plc
Endo International Plc is a publicly-traded pharmaceutical company that specializes in manufacturing and marketing pharmaceuticals and medical devices. The company headquarters is located in Dublin, Ireland, with additional offices and facilities in the United States, Canada, and Europe. Endo International Plc operates multiple subsidiaries, including Endo Pharmaceuticals, Par Pharmaceutical Companies, Qualitest Pharmaceuticals, and AMS (Amerigen Medical Specialties).
Endo International Plc's history can be traced back to the 1920s when it was established as The Endocrine Company. Over the next several decades, the company grew and diversified its product offerings. In 1997, it became known as Endo Pharmaceuticals Holdings Inc. and went public in 2000. Since then, Endo International Plc has undergone several strategic acquisitions and divestitures to focus on key therapeutic areas, including pain management, urology, and oncology.
Endo International Plc's product portfolio includes both branded and generic pharmaceuticals. Its branded products cater to various medical needs, including chronic pain, urological disorders, and endometriosis. Among its leading branded products are Lidoderm, Opana ER, Supprelin LA, and Vantas. In addition to branded pharmaceuticals, Endo International Plc also sells a range of generic medications under the Par label.
Aside from pharmaceuticals, Endo International Plc also offers medical devices through its AMS subsidiary. The company's leading medical device is the MiniArc Precise Single-Incision Sling System, which helps treat stress urinary incontinence in women.
In recent years, Endo International Plc has faced several challenges, including high debt and legal settlements. The company has taken steps to address these issues, including divesting non-core assets and restructuring its business operations.
Overall, Endo International Plc is a well-established pharmaceutical company that offers a diverse range of branded and generic drugs as well as medical devices. Despite facing challenges, the company has continued to invest in research and development and expand its product offerings, making it a significant player in the global pharmaceutical industry.
Company Address: First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin 4, 0
Company Phone Number: 1-268-2000 Stock Exchange / Ticker: ENDPQ
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Endo International Plc
Endo International Plc is a pharmaceutical company that recently released its financial results for the fiscal period of October to December 31, 2023. The company reported a significant increase in its loss per share, with a loss of $-10.38 per share compared to $-1.03 in the previous year. Additionally, the company experienced a substantial increase in its overall loss, with a net loss of $-2,441.483 million in the current reporting period, compared to a net loss of $-243.535 million in the same period a year ago.
The revenue for Endo International Plc declined by -10.449%, reaching $497.73 million in the recent reporting period, compared to $555.81 million in the previous year. However, there was a sequential increase in revenue from the prior reporting period, with a growth of 10.2% from $451.67 million. The decrease in revenue may be concerning as it indicates a decline in demand for the company's products.
|
| Products & Services
Published Mon, Jan 22 2024 9:30 PM UTC
Endo's Paladin Labs Launches XCOPRI in Canada, Providing New Treatment Option for Adults with Partial-Onset SeizuresMONTREAL, Jan. 22, 2024 - Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), made a groundbreaking announcement today, revealing the availability of XCOPRI (cenobamate tablets) in Canada. Designed as an adjunctive therapy, XCOPRI provides a...
|
| Endo International Plc
Endo International Plc (ENDP) has recently experienced a significant drop in its stock value, with a decline of -28.57% over the last five trading days. This decline has brought the year-to-date performance to a staggering -94%. Furthermore, the stock is currently trading at a significant -90.6% below its 52-week average. These numbers indicate a challenging period for the company.
When analyzing the financial data for the July to September 30, 2023, period, it is clear that Endo International Plc has faced some significant losses. The company reported a loss of $-0.12 per share during this period, compared to a loss of $-3.07 per share a year ago. Additionally, there was a decline in earnings per share from $0.10 in the preceding quarter.
|
| Endo International Plc
Endo International Plc, a leading pharmaceutical company, demonstrated a significant turnaround in its financial performance during the second quarter of 2023. The company reported an Income per Share of $0.10, a notable improvement compared to a loss of $8.02 per share in the same period last year, indicating a positive shift in profitability. Additionally, EPS turned positive from a loss of $0.01 per share from the previous reporting season.
Although Endo International Plc's revenues contracted by -3.912% year-on-year, generating $546.85 million in the Q2 of 2023 compared to $569.11 million in the corresponding period in 2022, there was a sequential increase of 6.13% from $515.27 million. This indicates a potential recovery trend for the company, despite facing a challenging market environment.
|
| Endo International Plc
Investors in the stock market have been closely following the performance of Endo International Plc over the past year and the first quarter of 2023. The company had a challenging year, posting a negative return on assets (ROA) of -48.19% due to a net loss of $-2 billion. However, the picture has been improving, and there are some exciting developments to look forward to.
Despite the company's struggles, there are several positive indicators visible. Within the healthcare sector, 256 other companies saw higher ROA. However, it's worth noting that Endo International Plc's overall ranking has been climbing throughout the quarter, improving to 1917 from the total ROA ranking in the fourth quarter of 2022 at 4497. This shows that the company is making progress, and investors can expect better results in the future.
|
| Per Share |
Current |
| Earnings (TTM) |
-10.41 $ |
| Revenues (TTM) |
8.56 $
|
| Cash Flow (TTM) |
- |
| Cash |
4.02 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-10.41 $
|
| Revenues (TTM) |
8.56 $ |
| Cash Flow (TTM) |
- |
| Cash |
4.02 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
